Takara Bio Reports on Cancer Drug Trial in China
May 5, 2008 -- Takara Bio Inc. (TSE: 4974) of Japan has begun a collaboration with Tianjin Cancer Institute & Hospital, Tianjin Medical University, under which Tianjin Cancer Institute & Hospital has initiated clinical research of a cancer immunotherapy developed by Takara. The new immunotherapy uses RetroNectin®, Takara’s proprietary recombinant human fibronectin, to expand T-cells. More details...